lung cancer gene and literature database Home
Cancer metastasis database

Annotation category 5

Literatures

Literature evidence

Links to all GeneRIF Items

10643

PubMed (Gene Name)

Literature evidence

17316760 (IGF2BP3)

study shows KOC is highly expressed in high-grade lung neuroendocrine carcinomas but not low- & intermediate-grade carcinoid tumors, indicating KOC may play an important role in regulation of biologic behavior of high-grade lung neuroendocrine carcinomas

19427669 (IGF2BP3)

IMP3 could play a critical role in diagnosis of non-small cell lung cancer, identifying high-risk patients who might benefit from early and tailored systemic therapy.

21838610 (IGF2BP3)

We review here the literature concerning IMP3 expression in lung neoplasms. IMP3 immunohistochemical expression was reported in 27-55% of cases of lung adenocarcinoma and in 75-90% of cases of lung squamous cell carcinoma. (review)

23190601 (IGF2BP3)

expression of IMP3 correlates with solid subtype and with distant metastases regardless of histological subtype of lung adenocarcinoma.

23661345 (IGF2BP3)

GLUT-1/KOC do not differentiate malignant mesotheliomas from pulmonary adenocarcinomas but can be useful in differentiating reactive mesothelial hyperplasia from malignant mesothelioma and lung adenocarcinoma.

23837977 (IGF2BP3)

IMP3 expression predicts a poor prognosis in the patients with lung squamous cell carcinoma, so it can be used as a novel lung carcinoma biomarker.

25337222 (IGF2BP3)

CK5/6, IMP3 and TTF1 immunostaining appears to be useful to improve the accuracy of cytological diagnoses between reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion

26608347 (IGF2BP3)

IMP3 appears to play an important role in tumor invasion in patients with lung adenocarcinoma and may serve as a useful prognostic biomarker in these patients.

28381175 (IGF2BP3)

IGF2BP3 might play the most important role in tumor aggressiveness and prognosis in lung adenocarcinoma.

29115542 (IGF2BP3)

Study found IMP3 frequently overexpressed in many human neoplasms and show significant associations with adverse tumor features in esophageal adenocarcinomas and cancers of the urinary bladder, lung, stomach, and pancreas.

29209838 (IGF2BP3)

IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.IMP3 expression is associated with poor prognosis in patients with non-small cell lung cancer brain metastases.

33493403 (IGF2BP3)

Prognostic Impact of IGF2BP3 expression in Patients with Surgically Resected lung Adenocarcinoma.